ESMO Young Oncologist Journal Club

The ESMO Young Oncologists Committee is proud to host the Young Oncologist Journal Club. On a regular basis (1-3 times a month), a committee member – or a specially invited young oncologists – provides you with an appraisal of an important clinical and/or translational article published in a major journal. The appraisers add their comments analysing the clinical relevance of the article and possible considerations.

Get involved by reading the review, share your thoughts and raise questions for discussion by logging in and commenting on the article. Commenting is reserved to ESMO Members only. We look forward to your input!

Submit an article


Topic Title Author
Breast cancer Combination of Anastrozole and Fulvestrant in Metastatic Breast Cancer Dimitrios Zardavas, Evandro de Azambuja
Central nervous system malignancies Lapatinib Plus Capecitabine in Patients with Previously Untreated Brain Metastases from HER2-Positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study Matthias Preusser
Gastrointestinal cancers Pancreatic Adenocarcinoma Treatment. Anticipating Better Results Konstaninos Kamposioras; Vassilios Papadopoulos
Breast cancer The Antibody-drug Conjugate Trastuzumab Emtansine (TDM-1) Significantly Prolongs Survival in HER2 Positive Advanced Breast Cancer Valentina Guarneri
Melanoma and other skin tumours Measuring the Steps Forward with MEK Inhibition in BRAF Mutant Advanced Melanoma: the METRIC Study Raffaele Califano; Vito Catalanotti
Genitourinary cancers Circulating Cytokines and Angiogenic Markers as Biomarkers for Pazopanib in Metastatic Renal Cell Carcinoma Joaquin Mateo
Lung and other thoracic tumours Lung Cancer Highlights from ASCO 2012 Marina C. Garassino; Eva R. Haspinger
Palliative and supportive care Supportive Care in Non-Small-Cell Lung Cancer Patients with Bone Metastasis Gilberto de Castro Junior
Gastrointestinal cancers Identification of a Poor Prognosis BRAF-Mutant–Like Population of Patients with Colon Cancer: a step forward towards personalised therapy Erika Martinelli
Breast cancer Pathologic Complete Response after Neoadjuvant Chemotherapy - the “pCRness” of breast cancer subtypes Evandro de Azambuja
Intratumour Heterogeneity: Does the strength of a tree lie in its trunk or in its branches? Leticia De Mattos-Arruda
Palliative and supportive care Patient Selection for Oncology Phase I Trials: a multi-institutional study of prognostic factors Jesus Corral
Sarcomas Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients with Advanced Bone and Soft Tissue Sarcomas Jörn Rüssel, MD
Gastrointestinal cancers Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition Through Feedback Activation of EGFR Matthias Preusser
Breast cancer FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer Tamer Refaat